Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.48 |
| ▸ | GCGR | P47871 | 4/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653039 | 0.93 | MRGPRX1 (0.51) | EGLN1GCGRPPARGMRGPRX1PIN1 | |
| SCHEMBL2652504 | 0.89 | KDM4E (0.43) | EGLN1GCGRPPARG | |
| SCHEMBL7116449 | 0.88 | GCGR (0.50) | EGLN1GCGRPPARGMRGPRX1GPR52 | |
| SCHEMBL2651098 | 0.86 | KDM4E (0.46) | GCGRPPARG | |
| SCHEMBL2652239 | 0.84 | GCGR (0.40) | EGLN1GCGRPPARG | |
| SCHEMBL7113992 | 0.83 | SMN1; SMN2 (0.43) | GCGRPPARG | |
| SCHEMBL2652296 | 0.83 | PPARG (0.49) | EGLN1GCGRPPARGMRGPRX1 | |
| SCHEMBL2652311 | 0.82 | HDAC1 (0.47) | EGLN1GCGRPPARGGPR52 | |
| SCHEMBL2651903 | 0.82 | HDAC1 (0.41) | GCGR | |
| SCHEMBL2651921 | 0.81 | VDR (0.43) | EGLN1GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | EGLN1 2105/4885GCGR 2/4885PPARG 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.